A team from Milmed/Longevience AB (Prof. Trevor Archer, Dr Axel Schumacher, Thomas Lenz and our Board member Johan Olsson participated in the 12th ARDD (Aging Research & Drug Discovery) in Copenhagen. In this symposium, leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of aging. Global thought-leaders sharing their latest insights into aging and how we target aging process ensuring everyone lives a healthier and… Read More »The Aging Research & Drug Discovery symposium in Copenhagen 25-29 August
Okategoriserade
In beginning of June our team with Trevor Archer, Thomas Lenz and Roger Karlsson visited Sapienza University and were informed about the last results obtained by Sapienza Team, taking advantage of C. elegans model to assay Milmed/AgeViva activity. Researchers involved in this study are Prof. Daniela Uccelletti, dr. Emily Schifano, Dr Federica Armeli, Beatrice Mengoni, and Prof. Rita Businaro. The results strengthened AgeViva’s positive anti-ageing effect and also showed a clear positive impact on mitochondria.
Milmed Unico subsidiary Longevience AB is starting a webshop for the launch of the anti-aging product AgeViva. AgeViva can be ordered at www.ageviva.se
A new Milmed article is published in the highly ranked MDPI journal: The Probiotic Yeast, Milmed, Promotes Autophagy and Antioxidant Pathways in BV-2 Microglia Cells and C. elegans. Read the article here.
Thomas Lenz participated in the The IPA World Congress + Probiota 2025, the leading Microbiome industry event 5 – 7 February, in Copenhagen. It was dynamic sessions, stimulating roundtable lunch discussions, information about the latest insights from the industry and interesting meetings and networking.
A collaboration Agreement with a chinese partner was signed for introducing AgeViva as a antiaging food supplement product in China. The work with the inlicensing in China have already started after the signing of the contract January 13.
A new production of our patented yeast is being produced by Jästbolaget ahead of the launch of our patented anti-aging product AgeViva™ in Q1 2025.
Our trademark AgeViva™ was approved Nov 29.
Trevor Archer, Thomas Lenz and Roger Karlsson visited Sapienza University Nov 25-28. The team at Sapienza with professor Rita Businaro presented new results in antiaging studies. The presentation showed new very positive and strong study results for the important hallmarks of longevity/antiaging: autophagy, anti-inflammageing and anti-oxidative stress
Trevor Archer and Thomas Lenz, has participated in the 30th annual which took place this year in Stockholm November 4-6. BIO-Europé is one of the top pharma events in Europe. The BIO-Europe program explores the impact of the Swedish approach, embodied by an openness to collaboration, has had on biotech innovation, and addresses the latest trends, challenges and opportunities in life science. Milmed received a lot of positive interest in its new patented longevity/antiaging product.… Read More »30th annual BIO-Europe